Bavarian Nordic beendet die RSV-Impfstoff-Entwicklung, nachdem eine Studie an Älteren die Studienziele verfehlte.
Bavarian Nordic ends RSV vaccine programme after poor trial results | Reuters
Denmark-based Bavarian Nordic said on Saturday it was ending its respiratory syncytial virus (RSV) vaccine programme as its Phase 3 clinical trial did not meet all the primary goals of preventing lower respiratory tract disease.